Mirum Pharmaceuticals, Inc. MIRM R2KR3KPHARMA
Company Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $521.31M (+54.7% YoY); net profit $-23.36M.
- Trailing 12 Months Year-on-year growth — revenue +37.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 37.90% |
Stock Price Performance
| 1 Year: | +23.41% |
| 6 Months: | -12.13% |
| 3 Months: | -29.61% |
| 1 Month: | -10.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 37.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MIRM Mirum Pharmaceuticals, Inc. R2KR3KPHARMA | 80.39 | -5.71 | $5.22B | 0.00% | -3.47% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 0 | 11.00M | 5.00M | 12.89M | 17.48M | 18.78M | 31.60M | 37.50M | 47.73M | 69.22M | 77.88M | 90.38M | 111.58M | 127.78M | 133.01M | 159.88M | 176.24M |
| Operating Income | -65.00K | -6.18M | -14.03M | -15.87M | -22.03M | -23.60M | -21.72M | -47.61M | -37.40M | -42.82M | -32.74M | -31.44M | -32.88M | -27.15M | -24.27M | -25.15M | -26.47M | -24.23M | -12.68M | -15.18M | -4.99M | 2.60M | -789.47M | -42.54M |
| Net Income | -67.00K | -5.96M | -13.56M | -15.09M | -21.31M | -23.25M | -21.51M | -50.53M | -43.89M | -47.11M | -36.61M | -26.92M | -35.71M | -30.13M | -74.04M | -23.59M | -25.28M | -24.64M | -14.23M | -14.68M | -5.86M | 2.90M | -790.15M | -67.23M |
| Diluted EPS | - | - | - | - | - | - | - | - | -1.45 | -1.55 | -1.17 | -0.84 | -1.02 | -0.80 | -1.94 | -0.57 | -0.54 | -0.52 | -0.30 | -0.30 | -0.12 | 0.05 | -13.43 | -1.06 |
| R&D Expense | 3.00K | - | 11.59M | 12.16M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 19.14M | 77.06M | 186.37M | 336.89M | 521.31M |
| Operating Income | -54.74M | -104.30M | -173.41M | -131.22M | -109.15M | -87.61M | -22.14M |
| Net Income | -52.55M | -103.27M | -83.99M | -135.66M | -163.41M | -87.94M | -23.36M |
| Diluted EPS | - | - | -2.77 | -4.02 | -4.00 | -1.85 | -0.47 |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 51.98M | 146.71M | 240.86M | 294.65M | 352.91M | 646.62M | 670.75M | 842.81M |
| Total Equity | 0 | -17.31M | 130.35M | 172.09M | 120.21M | 142.04M | 248.67M | 225.64M | 314.69M |
| Cash & Equivalents | - | 51.96M | 11.97M | 142.09M | 31.34M | 28.00M | 286.33M | 222.50M | 296.68M |
| Total Liabilities | - | 2.45M | 16.36M | 68.77M | 174.44M | 210.87M | 397.95M | 445.11M | 528.12M |
| Current Liabilities | - | 2.45M | 13.08M | 18.46M | 42.60M | 64.73M | 87.06M | 126.55M | 205.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -39.36M | -89.08M | -132.76M | -120.14M | -70.94M | 10.32M | 55.83M |
| Investing Cash Flow | -127.78M | 37.87M | 48.55M | 7.70M | -107.20M | -90.12M | -23.95M |
| Financing Cash Flow | 127.18M | 181.29M | 73.47M | 109.09M | 336.60M | 17.70M | 40.14M |
| Capital Expenditure | -281.00K | -225.00K | -24.00K | -278.00K | -109.00K | -993.00K | -954.00K |
| Free Cash Flow | -39.64M | -89.30M | -132.78M | -120.41M | -71.05M | 9.33M | 54.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Net Margin % | - | - | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| ROE % | -40.3% | -60.0% | -69.9% | -95.5% | -65.7% | -39.0% | -7.4% |
| ROCE % | -41.0% | -46.9% | -68.8% | -45.5% | -19.5% | -16.1% | -3.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 11.83% | 7.68M | $660.53M |
| 2 | Jupiter Topco LLC | 9.10% | 5.91M | $508.25M |
| 3 | Blackrock Inc. | 6.76% | 4.39M | $377.59M |
| 4 | FMR, LLC | 5.65% | 3.67M | $315.68M |
| 5 | Price (T.Rowe) Associates Inc | 4.09% | 2.66M | $228.41M |
| 6 | Vanguard Portfolio Management LLC | 3.66% | 2.38M | $204.45M |
| 7 | Vanguard Capital Management LLC | 3.47% | 2.25M | $193.88M |
| 8 | State Street Corporation | 3.34% | 2.17M | $186.70M |
| 9 | William Blair Investment Management, LLC | 2.16% | 1.40M | $120.82M |
| 10 | Geode Capital Management, LLC | 2.15% | 1.39M | $119.89M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MIRM
MIRM Dec 2026 145.000 call (MIRM261218C00145000) stock price, news, quote and history - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBsUGtsT3NsYmd3SWRtRHZlSTR6bjZfSUs4WWZYMmwtbFRoeEVILWxpaDU4b2x6MGo1UFZuQ0lXelFSUU9yeVMxUUw1WlgzdzlETWFoWHZqanlqckJIdktjS05PajNTdw?oc=5" target="_blank">MIRM Dec 2026 145.000 call (M…
Mirum Pharmaceuticals, Inc. Estimates – NASDAQ:MIRM - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1CYlA1aTVYNmpiVmFWUjFMOWlVRlR0WHdHbWNyT1VLa2ZSQTNvU0l2NDRFVU1qNzAtMl9MX3RSa2loSUZVRUQ1eXFNRkgxc193SUt3WF9hWDdOQXpNZW9LM2NfYUZZaG5pRHFBM2N0NjlfVWlxTGltVQ?oc=5" target="_blank">Mirum…
How Mirum Pharmaceuticals Inc. (MIRM) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNTTRYbEdQeG5BaF94enlCN1NuS0wwMnRfdW9JZlYxQzhBd1phdEVycm83RVpQZWdaclprZXRNenJqQ0lRMlcwZ3ZGLUxnVTg0VlVsd2dxbW03TU9NRGxGMHdlLWcwYl9MeGcteW1ZVUVUdHIwTGNfRGZPSU03dFBHem1YXzB1QzFuNXdrbk…
How Investors May Respond To Mirum Pharmaceuticals (MIRM) Phase 3 Trial Success - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOWHZMZWdGSHRBMkJzWUhQWnJMQ3VtS0wzck83UmdsakFHelJCQm9Zd3E2V3J2clJwd1dTWENCUWlaNHptY1V2dXFDcWkyZGxhWTNKMHozWTFvejVfZ250ZzhmSEFxNG05M0d2MFVZMGl4WU93NnNnN1pKc1hhd1AyMmZyblFHN0E3TTduUn…
MIRM270115P00085000 Interactive Stock Chart | MIRM Jan 2027 85.000 put Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE5rQ2ZQZEpySXZ5YV96MVFDMGhIbDlSR2ZXTGNjSUNXUVkyX1d1a2RLcVZibG93TU13SXZ4cUp2MThkVWhjU2Q3SjRaeVpRaWFrQ0tGcm9qalZZLW9JUnVTag?oc=5" target="_blank">MIRM270115P00085000 Interactive Stock…
MIRM Jan 2027 120.000 call (MIRM270115C00120000) stock historical prices and data - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFBVTlF4THh6cUphZjNMcEpwVVRiamhoeU9jczFYbnk0T2lkbTZjQ2tkb2xuREw3NXpsbWFZMEh1aDJaaXpqOUY3OWxWZnhjSnJac2xGSG5VbGZsSHRkN003TzctU0UzcE85cHEwYUtId1k?oc=5" target="_blank">MIRM Jan 2027 12…
MIRM — Frequently Asked Questions
What is the current share price of Mirum Pharmaceuticals, Inc. (MIRM)?
As of 2026-10-23 16:27 PDT, Mirum Pharmaceuticals, Inc. (MIRM) trades at $80.39 on NasdaqGM. Its 52-week range is $64.10 to $128.57.
What is the market capitalisation of MIRM?
Mirum Pharmaceuticals, Inc. (MIRM) has a market capitalisation of $5.22B on NasdaqGM.
What is the P/E ratio of MIRM?
MIRM trades at a trailing price-to-earnings (P/E) ratio of -5.71. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -570.37.
Is MIRM a good stock to buy?
This page provides a data-driven analysis of Mirum Pharmaceuticals, Inc. (MIRM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.